FDA quietly halts publication of vaccine studies
2026-05-06
Silence is now the most telling signal in the federal vaccine debate. Publication of two government-funded studies on covid and shingles vaccines has been halted by the Food and Drug Administration, according to people familiar with the work and internal correspondence, freezing analyses that were expected to inform clinicians and policy makers.
The move lands awkwardly after a separate decision by the Centers for Disease Control and Prevention not to publish a report indicating that the most recent covid vaccine reduced the risk of hospitalization, based on real‑world effectiveness data and standard incidence‑rate ratios. Where agencies once flooded journals and preprint servers with immunogenicity curves, confidence intervals and pharmacovigilance signals, they are now choosing selective disclosure, inviting suspicion that political optics are being weighed alongside biostatistics.
Critics argue that withholding methodologically sound findings, whether flattering or not, undermines evidence‑based medicine by limiting external peer review and independent meta‑analysis. Defenders inside the agencies hint at concerns over misinterpretation, data misappropriation and the strain of constant information warfare, yet those explanations do little to reassure clinicians who must interpret breakthrough infections, waning neutralizing antibody titers and rare adverse events without full access to government data.
Loading...
